Author: "Nyssen, Olga P." - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Nyssen, Olga P."' showing total 214 results

Start Over Author "Nyssen, Olga P."

214 results on '"Nyssen, Olga P."'

1. Author Correction: Comparison of the management of Helicobacter pylori infection between the older and younger European populations

Author: Jonaitis, Paulius, Nyssen, Olga P., Saracino, Ilaria Maria, Fiorini, Giulia, Vaira, Dino, Pérez-Aísa, Ángeles, Tepes, Bojan, Castro-Fernandez, Manuel, Pabón-Carrasco, Manuel, Keco-Huerga, Alma, Voynovan, Irina, Lucendo, Alfredo J., Lanas, Ángel, Martínez-Domínguez, Samuel J., Almajano, Enrique Alfaro, Rodrigo, Luis, Vologzanina, Ludmila, Brglez Jurecic, Natasa, Denkovski, Maja, Bujanda, Luis, Mahmudov, Umud, Leja, Mārcis, Lerang, Frode, Babayeva, Gülüstan, Bordin, Dmitry S., Gasbarrini, Antonio, Kupcinskas, Juozas, Gridnyev, Oleksiy, Rokkas, Theodore, Marcos-Pinto, Ricardo, Phull, Perminder S., Smith, Sinead M., Tonkić, Ante, Boltin, Doron, Buzás, György Miklós, Šembera, Štěpán, Şimşek, Halis, Matysiak-Budnik, Tamara, Milivojevic, Vladimir, Marlicz, Wojciech, Venerito, Marino, Boyanova, Lyudmila, Doulberis, Michael, Capelle, Lisette G., Cano-Català, Anna, Moreira, Leticia, Mégraud, Francis, O’Morain, Colm, Gisbert, Javier P., and Jonaitis, Laimas
Published: 2023
Full Text: View/download PDF

2. Comparison of the management of Helicobacter pylori infection between the older and younger European populations

Author: Jonaitis, Paulius, Nyssen, Olga P., Saracino, Ilaria Maria, Fiorini, Giulia, Vaira, Dino, Pérez-Aísa, Ángeles, Tepes, Bojan, Castro-Fernandez, Manuel, Pabón-Carrasco, Manuel, Keco-Huerga, Alma, Voynovan, Irina, Lucendo, Alfredo J., Lanas, Ángel, Martínez-Domínguez, Samuel J., Almajano, Enrique Alfaro, Rodrigo, Luis, Vologzanina, Ludmila, Brglez Jurecic, Natasa, Denkovski, Maja, Bujanda, Luis, Mahmudov, Umud, Leja, Mārcis, Lerang, Frode, Babayeva, Gülüstan, Bordin, Dmitry S., Gasbarrini, Antonio, Kupcinskas, Juozas, Gridnyev, Oleksiy, Rokkas, Theodore, Marcos-Pinto, Ricardo, Phull, Perminder S., Smith, Sinead M., Tonkić, Ante, Boltin, Doron, Buzás, György Miklós, Šembera, Štěpán, Şimşek, Halis, Matysiak-Budnik, Tamara, Milivojevic, Vladimir, Marlicz, Wojciech, Venerito, Marino, Boyanova, Lyudmila, Doulberis, Michael, Capelle, Lisette G., Cano-Català, Anna, Moreira, Leticia, Mégraud, Francis, O’Morain, Colm, Gisbert, Javier P., and Jonaitis, Laimas
Published: 2023
Full Text: View/download PDF

3. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

Author: Fiorinni, Giulia, Saracino, Ilaria Maria, Carrasco, Manuel Pabon, Huerga, Alma Keco, Almajano, Enrique Alfaro, Martinez Dominguez, Samuel Jesus, Galan, Horacio Alonso, Velayos, Benito, Sadornil, Carmen Dueñas, Botargues Bote, Jose Maria, Gonzalez-Cordero, Pedro Luis, Areia, Miguel, Gomez Rodriguez, Blas Jose, Pellicano, Rinaldo, Nuñez, Óscar, Franceschi, Francesco, Alekseenko, Sergey, Perona, Monica, Abdulkhakov, Rustam, Dominguez-Cajal, Manuel, Notari, Pedro Almela, Camarero, Judith Gomez, Moreno, Manuel Jimenez, Algaba, Alicia, Bermejo, Fernando, Tejada, Javier Tejedor, Susanibar, Elida Oblitas, Boltin, Doron, Georgopoulos, Sotirios, OMorain, Colm, Qasim, Asghar, Beales, Ian, Bakulina, Natalia, Fadeenko, Galina, Malfertheiner, Peter, Rosania, Rosa, Ilchishina, Tatiana, Bogomolov, Pavel, Bakulin, Igor, Zaytsev, Oleg, Gravina, Antonietta Gerarda, Romano, Marco, Di Leo, Alfredo, Losurdo, Giuseppe, Grigorieva, Ludmila, Guillena, Pedro Delgado, Marusic, Marinko, Jurcic, Dragan, Dekhnich, Natalia Nikolaevna, Iyo, Eduardo, de la Peña Negro, Luisa Carmen, Baryshnikova, Natalia, Bakanova, Natalia, Simsek, Halis, Simsek, Cem, Gridnyev, Oleksiy, Fernandez-Bermejo, Miguel, Angueira, Teresa, Ruiz-Zorrilla Lopez, Rafael, Gomez, Barbara, Kovacheva-Slavova, Mila, Lahat, Adi, Alcedo, Javier, Campillo, Ana, Belousova, Liya Nikolaevna, Villarroya, Ramon Pajares, Ljubicic, Neven, Nikolic, Marko, González-Santiago, Jesús M., Santamaría, Diego Burgos, Pakhomova, Anna, Sekulic-Spasic, Izabela, Ghisa, Matteo, Farinati, Fabio, Sagdati, Sabir Irfan, Panic, Nikola, Heluwaert, Frederic, Amorena, Edurne, Moreira, Leticia, Esparrach, Gloria Fernandez, Plotnikova, Ekaterina Yuryevna, Kukla, Michal, Kamburov, Victor, Lamuela Calvo, Luis Javier, Rankovic, Ivan, Lavín, Antonio Cuadrado, Lazaro, Yolanda Arguedas, Carrera Agnieszka Dobrowolska, Victor Gonzalez, Eder, Piotr, Kononova, Alla, Nyssen, Olga P., Vaira, Dino, Pérez Aísa, Ángeles, Rodrigo, Luis, Castro-Fernandez, Manuel, Jonaitis, Laimas, Tepes, Bojan, Vologzhanina, Liudmila, Caldas, María, Lanas, Angel, Lucendo, Alfredo J., Bujanda, Luis, Ortuño, Juan, Barrio, Jesús, Huguet, Jose M., Voynovan, Irina, Lasala, Jorge Perez, Sarsenbaeva, Aiman Silkanovna, Fernandez-Salazar, Luis, Molina-Infante, Javier, Jurecic, Natasa Brglez, Gasbarrini, Antonio, Kupčinskas, Juozas, Bordin, Dmitry, Marcos-Pinto, Ricardo, Lerang, Frode, Leja, Marcis, Buzas, Gyorgy M., Niv, Yaron, Rokkas, Theodore, Phull, Perminder, Smith, Sinead, Shvets, Oleg, Venerito, Marino, Milivojevic, Vladimir, Simsek, Ilkay, Lamy, Vincent, Bytzer, Peter, Boyanova, Lyudmila, Kunovský, Lumír, Beglinger, Christoph, Doulberis, Michael, Marlicz, Wojciech, Goldis, Adrian, Tonkić, Ante, Capelle, Lisette, Puig, Ignasi, Megraud, Francis, Morain, Colm O’, and Gisbert, Javier P.
Published: 2022
Full Text: View/download PDF

4. V Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori

Author: Gisbert, Javier P., Alcedo, Javier, Amador, Javier, Bujanda, Luis, Calvet, Xavier, Castro-Fernández, Manuel, Fernández-Salazar, Luis, Gené, Emili, Lanas, Ángel, Lucendo, Alfredo J., Molina-Infante, Javier, Nyssen, Olga P., Pérez-Aisa, A., and Puig, Ignasi
Published: 2022
Full Text: View/download PDF

5. Clinical Practice Guidelines. V Spanish Consensus Conference on Helicobacter pylori infection treatment

Author: Gisbert, Javier P., Alcedo, Javier, Amador, Javier, Bujanda, Luis, Calvet, Xavier, Castro-Fernandez, Manuel, Fernandez-Salazar, Luis, Gene, Emili, Lanas, Angel, Lucendo, Alfredo J., Molina-Infante, Javier, Nyssen, Olga P., Perez-Aisa, A., and Puig, e Ignasi
Published: 2021
Full Text: View/download PDF

6. Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp‐EuReg)

Author: Universidad de Sevilla. Departamento de Enfermería, Martínez‐Domínguez, Samuel J., Nyssen, Olga P., Lanas, Ángel, Alfaro, Enrique, Jonaitis, Laimas, Mahmudov, Umud, Pabón Carrasco, Manuel, Gisbert, Javier P., Universidad de Sevilla. Departamento de Enfermería, Martínez‐Domínguez, Samuel J., Nyssen, Olga P., Lanas, Ángel, Alfaro, Enrique, Jonaitis, Laimas, Mahmudov, Umud, Pabón Carrasco, Manuel, and Gisbert, Javier P.
Abstract: Background: The influence of indications for Helicobacter pylori investigation on prescriptions and effectiveness is unknown. The aim of the study was to assess the impact of indications for H. pylori investigation on prescriptions, effectiveness, compliance, and tolerance. Methods: International, prospective, non-interventional registry of the management of H. pylori infection by European gastroenterologists (Hp-EuReg). Treatment-näive patients registered from 2013 to 2023 at e-CRF AEG-REDCap were analyzed. The effectiveness was assessed by modified intention-to-treat analysis. Results: Overall, 53,636 treatment-naïve cases from 34 countries were included. Most frequent indications were: dyspepsia with normal endoscopy (49%), non-investigated dyspepsia (20%), duodenal ulcer (11%), gastric ulcer (7.7%), and gastroesophageal reflux disease (GERD) (2.6%). Therapy effectiveness varied by indication: duodenal ulcer (91%), gastric ulcer (90%), preneoplastic lesions (90%), dyspepsia with normal endoscopy (89%), GERD (88%), and non-investigated dyspepsia (87%). Bismuth-metronidazole-tetracycline and clarithromycin-amoxicillin-bismuth quadruple therapies achieved 90% effectiveness in all indications except GERD. Concomitant clarithromycin-amoxicillin-tinidazole/metronidazole reached 90% cure rates except in patients with non-investigated dyspepsia; whereas sequential clarithromycin-amoxicillin-tinidazole/metronidazole proved optimal (≥90%) in patients with gastric ulcer only. Adverse events were higher in patients treated for dyspepsia with normal endoscopy and duodenal ulcer compared with the remaining indications (23% and 28%, p < 0.001). Therapeutic compliance was higher in patients with duodenal ulcer and preneoplastic lesions (98% and 99%, p < 0.001). Conclusion: In Europe, patients with gastric or duodenal ulcers and preneoplastic lesions showed higher H. pylori treatment effectiveness. Bismuth and non-bismuth quadruple therapies achieved optimal results in almost all
Published: 2024

7. Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp‐EuReg).

Author: Martínez‐Domínguez, Samuel J., Nyssen, Olga P., Lanas, Ángel, Alfaro, Enrique, Jonaitis, Laimas, Mahmudov, Umud, Voynovan, Irina, Gülüstan, Babayeva, Rodrigo, Luis, Fiorini, Giulia, Perez‐Aisa, Ángeles, Tejedor‐Tejada, Javier, Tepes, Bojan, Vologzanina, Ludmila, Mammadov, Emin, Lerang, Frode, Oğlu, Quliyev Fərid Vidadi, Bakulina, Natalia V., Abdulkhakov, Rustam, and Tatiana, Ilchishina
Subjects: *STOMACH ulcers, *PRECANCEROUS conditions, *HELICOBACTER pylori, *GASTROESOPHAGEAL reflux, *INDIGESTION, *DUODENAL ulcers
Abstract: Background: The influence of indications for Helicobacter pylori investigation on prescriptions and effectiveness is unknown. The aim of the study was to assess the impact of indications for H. pylori investigation on prescriptions, effectiveness, compliance, and tolerance. Methods: International, prospective, non‐interventional registry of the management of H. pylori infection by European gastroenterologists (Hp‐EuReg). Treatment‐näive patients registered from 2013 to 2023 at e‐CRF AEG‐REDCap were analyzed. The effectiveness was assessed by modified intention‐to‐treat analysis. Results: Overall, 53,636 treatment‐naïve cases from 34 countries were included. Most frequent indications were: dyspepsia with normal endoscopy (49%), non‐investigated dyspepsia (20%), duodenal ulcer (11%), gastric ulcer (7.7%), and gastroesophageal reflux disease (GERD) (2.6%). Therapy effectiveness varied by indication: duodenal ulcer (91%), gastric ulcer (90%), preneoplastic lesions (90%), dyspepsia with normal endoscopy (89%), GERD (88%), and non‐investigated dyspepsia (87%). Bismuth‐metronidazole‐tetracycline and clarithromycin‐amoxicillin‐bismuth quadruple therapies achieved 90% effectiveness in all indications except GERD. Concomitant clarithromycin‐amoxicillin‐tinidazole/metronidazole reached 90% cure rates except in patients with non‐investigated dyspepsia; whereas sequential clarithromycin‐amoxicillin‐tinidazole/metronidazole proved optimal (≥90%) in patients with gastric ulcer only. Adverse events were higher in patients treated for dyspepsia with normal endoscopy and duodenal ulcer compared with the remaining indications (23% and 28%, p < 0.001). Therapeutic compliance was higher in patients with duodenal ulcer and preneoplastic lesions (98% and 99%, p < 0.001). Conclusion: In Europe, patients with gastric or duodenal ulcers and preneoplastic lesions showed higher H. pylori treatment effectiveness. Bismuth and non‐bismuth quadruple therapies achieved optimal results in almost all indications. Trial Registration: ClinicalTrials.gov identifier: NCT02328131. [ABSTRACT FROM AUTHOR]
Published: 2024
Full Text: View/download PDF

8. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients

Author: McNicholl, Adrian G., Bordin, Dmitry S., Lucendo, Alfredo, Fadeenko, Galina, Fernandez, Manuel Castro, Voynovan, Irina, Zakharova, Natalia Valerievna, Sarsenbaeva, Aiman Silkanovna, Bujanda, Luis, Perez-Aisa, Ángeles, Vologzhanina, Liudmila, Zaytsev, Oleg, Ilchishina, Tatiana, Coba, Cristobal de la, Lasala, Jorge Perez, Alekseenko, Sergey, Modolell, Ines, Molina-Infante, Javier, Ruiz-Zorrilla Lopez, Rafael, Alonso-Galan, Horacio, Moreno, Nuria Fernandez, Hinojosa, Jen, Santaella, Inmaculada, Varela, Pilar, Gonzalez-Cordero, Pedro Luis, Barrio, Jesus, Dominguez-Jimenez, Jose Luis, Nuñez, Oscar, Alcedo, Javier, Nyssen, Olga P., Caldas, Maria, Donday, Maria G., Shvetz, Oleg, Megraud, Francis, O'Morain, Colm, and Gisbert, Javier P.
Published: 2020
Full Text: View/download PDF

9. Sequential versus Standard Triple Therapy for First-Line Helicobacter pylori Eradication: An Update

Author: Nyssen, Olga P., primary, Martínez, Belén, additional, Mégraud, Francis, additional, Savarino, Vincenzo, additional, Fallone, Carlo A., additional, Bazzoli, Franco, additional, and Gisbert, Javier P., additional
Published: 2024
Full Text: View/download PDF

10. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance

Author: Bujanda, Luis, primary, Nyssen, Olga P., additional, Ramos, June, additional, Bordin, Dmitry S., additional, Tepes, Bojan, additional, Perez-Aisa, Angeles, additional, Pavoni, Matteo, additional, Castro-Fernandez, Manuel, additional, Lerang, Frode, additional, Leja, Mārcis, additional, Rodrigo, Luis, additional, Rokkas, Theodore, additional, Kupcinskas, Juozas, additional, Jonaitis, Laimas, additional, Shvets, Oleg, additional, Gasbarrini, Antonio, additional, Simsek, Halis, additional, Phull, Perminder S., additional, Buzás, György Miklós, additional, Machado, Jose C., additional, Boltin, Doron, additional, Boyanova, Lyudmila, additional, Tonkić, Ante, additional, Marlicz, Wojciech, additional, Venerito, Marino, additional, Vologzanina, Ludmila, additional, Fadieienko, Galina D., additional, Fiorini, Giulia, additional, Resina, Elena, additional, Muñoz, Raquel, additional, Cano-Català, Anna, additional, Puig, Ignasi, additional, García-Morales, Natalia, additional, Hernández, Luis, additional, Moreira, Leticia, additional, Megraud, Francis, additional, Morain, Colm O., additional, Montes, Milagrosa, additional, and Gisbert, Javier P., additional
Published: 2024
Full Text: View/download PDF

11. Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg)

Author: Nyssen, Olga P., Vaira, Dino, Tepes, Bojan, Kupcinskas, Limas, Bordin, Dmitry, Pérez-Aisa, Ángeles, Gasbarrini, Antonio, Castro-Fernández, Manuel, Bujanda, Luis, Garre, Ana, Lucendo, Alfredo, Vologzhanina, Liudmila, Jurecic, Natasa B., Rodrigo-Sáez, Luis, Huguet, Jose M., Voynovan, Irina, Perez-Lasala, Jorge, Romero, Pilar Mata, Vujasinovic, Miroslav, Abdulkhakov, Rustam, Barrio, Jesús, Fernandez-Salazar, Luis, Mégraud, Francis, O’Morain, Colm, and Gisbert, Javier P.
Published: 2022
Full Text: View/download PDF

12. Role of compliance in Helicobacter pylorieradication treatment: Results of the European Registry on H. pylorimanagement

Author: Huguet, Jose M., Ferrer‐Barceló, Luis, Suárez, Patrícia, Barcelo‐Cerda, Susana, Sempere, Javier, Saracino, Ilaria Maria, Fiorini, Giulia, Vaira, Dino, Pérez‐Aísa, Ángeles, Jonaitis, Laimas, Tepes, Bojan, Castro‐Fernandez, M., Pabón‐Carrasco, Manuel, Keco‐Huerga, Alma, Voynovan, Irina, Lucendo, Alfredo J., Lanas, Ángel, Martínez‐Domínguez, Samuel J., Alfaro Almajano, Enrique, Rodrigo, Luis, Vologzanina, Ludmila, Bordin, Dmitry S., Gasbarrini, Antonio, Babayeva, Gülüstan, Lerang, Frode, Leja, Mārcis, Kupčinskas, Juozas, Rokkas, Theodore, Marcos‐Pinto, Ricardo, Meštrović, Antonio, Gridnyev, Oleksiy, Phull, Perminder S., Smith, Sinead M., Boltin, Doron, Buzás, György Miklós, Kral, Jan, Şimşek, Halis, Matysiak‐Budnik, Tamara, Milivojevic, Vladimir, Marlicz, Wojciech, Venerito, Marino, Boyanova, Lyudmila, Doulberis, Michael, Capelle, Lisette G., Cano‐Català, Anna, Moreira, Leticia, Nyssen, Olga P., Mégraud, Francis, O’Morain, Colm, and Gisbert, Javier P.
Abstract: Adherence to Helicobacter pylori (H. pylori)eradication treatment is a cornerstone for achieving adequate treatment efficacy. To determine which factors influence compliance with treatment. A systematic prospective non‐interventional registry (Hp‐EuReg) of the clinical practice of European gastroenterologists. Compliance was considered adequate if ≥90% drug intake. Data were collected until September 2021 using the AEG‐REDCap e‐CRF and were subjected to quality control. Modified intention‐to‐treat analyses were performed. Multivariate analysis carried out the factors associated with the effectiveness of treatment and compliance. Compliance was inadequate in 646 (1.7%) of 38,698 patients. The non‐compliance rate was higher in patients prescribed longer regimens (10‐, 14‐days) and rescue treatments, patients with uninvestigated dyspepsia/functional dyspepsia, and patients reporting adverse effects. Prevalence of non‐adherence was lower for first‐line treatment than for rescue treatment (1.5% vs. 2.2%; p< 0.001). Differences in non‐adherence in the three most frequent first‐line treatments were shown: 1.1% with proton pump inhibitor + clarithromycin + amoxicillin; 2.3% with proton pump inhibitor clarithromycin amoxicillin metronidazole; and 1.8% with bismuth quadruple therapy. These treatments were significantly more effective in compliant than in non‐compliant patients: 86% versus 44%, 90% versus 71%, and 93% versus 64%, respectively (p< 0.001). In the multivariate analysis, the variable most significantly associated with higher effectiveness was adequate compliance (odds ratio, 6.3 [95%CI, 5.2–7.7]; p< 0.001). Compliance with Helicobacter pylorieradication treatment is very good. Factors associated with poor compliance include uninvestigated/functional dyspepsia, rescue‐treatment, prolonged treatment regimens, the presence of adverse events, and the use of non‐bismuth sequential and concomitant treatment. Adequate treatment compliance was the variable most closely associated with successful eradication.
Published: 2024
Full Text: View/download PDF

13. Reply

Author: Nyssen, Olga P., primary and Gisbert, Javier P., additional
Published: 2023
Full Text: View/download PDF

14. Safety profile of Helicobacter pylorieradication treatments: literature review and updated data of the European Registry on Helicobacter pylorimanagement (Hp-EuReg)

Author: Luzko, Irina, P. Nyssen, Olga, Moreira, Leticia, and Gisbert, Javier P.
Abstract: ABSTRACTIntroductionHelicobacter pylori(H. pylori), the most prevalent chronic infection globally, is the major cause of relevant diseases such as gastric cancer, leading to high morbidity and mortality worldwide. Several studies have focused on optimize H. pylorieradication treatment through combination therapies and antibiotic resistance. However, the adverse events profile and its impact, as a primary outcome, remains underexplored.The aim of this review was to summarize the available data on the safety of the most common regimens for H. pylorieradication and its impact on the compliance.Areas coveredThis review encompassed the published evidence from the years 2008 to 2023 regarding both the safety and compliance for most common H. pylori eradication regimens. The main sources for this review comprised MEDLINE, PubMed, and Cochrane electronic databases. Furthermore, it included a safety analysis of unpublished data from the European Registry on H. pylorimanagement (Hp-EuReg).Expert opinionPoor compliance is correlated with significantly lower cure rates, and this is a unique modifiable source of H. pylori treatment failure. Eradication treatments have become complex, involving multiple drugs and dosing intervals. Thus, patient education is crucial; doctors must explain to the patient about potential temporary and most often harmless side effects.
Published: 2024
Full Text: View/download PDF

15. Accuracy of the Ultra-Rapid Urease Test for diagnosis of Helicobacter pylori infection

Author: McNicholl, Adrian Gerald, Ducons, Julio, Barrio, Jesús, Bujanda, Luis, Forné-Bardera, Montserrat, Aparcero, Reyes, Ponce, Julio, Rivera, Robin, Dedeu-Cuso, José María, Garcia-Iglesias, Pilar, Montoro, Miguel, Bejerano, Alicia, Ber-Nieto, Yolanda, Madrigal, Belen, Zapata, Eva, Loras-Alastruey, Carmen, Castro, Manuel, Nevarez, Andrea, Mendez, Isabel, Bory-Ros, Felipe, Miquel-Planas, Mireia, Vera, Isabel, Nyssen, Olga P., and Gisbert, Javier P.
Published: 2017
Full Text: View/download PDF

16. Helicobacter pylori treatment results in Slovenia in the period 2013-2015 as a part of European Registry on Helicobacter pylori Management

Author: Tepes Bojan, Kastelic Marko, Vujasinovic Miroslav, Lampic Polona, Seruga Maja, Jurecic Natasa Brglez, Nyssen Olga P., Donday Maria G., O’Morain Colm, Megraud Francis, McNicholl Adrian G, and Gisbert Javier P.
Subjects: helicobacter pylori, eradication treatment, european registry on helicobacter pylori management, slovenian results, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract: Helicobacter pylori (H. pylori) is the most common chronic bacterial infection in the world affecting over 50% of the world’s population. H. pylori is a grade I carcinogen, responsible for the development of 89 % of noncardia gastric cancers. In the present study we analyzed the data for H. pylori eradication treatments in Slovenia.
Published: 2017
Full Text: View/download PDF

17. Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management

Author: Gatta, Gian Luigi, Nyssen, Olga P, Fiorini, Giulia, Saracino, Ilaria Maria, Pavoni, Matteo, Romano, Marco, Gravina, Antonietta Gerarda, Granata, Lucia, Pellicano, Rinaldo, Gasbarrini, Antonio, Di Leo, Alfredo, Losurdo, Giuseppe, Franceschi, Francesco, Nardone, Gerardo, Rocco, Alba, Dore, Maria Pina, Farinati, Fabio, Ghisa, Matteo, Bellini, Massimo, Holton, John, Puig, Ignasi, Vaira, Dino, Borghi, Claudio, Mégraud, Franci, O'Morain, Colm, Gisbert, Javier P, Gatta, Luigi, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Franceschi, Francesco (ORCID:0000-0001-6266-445X), Gatta, Gian Luigi, Nyssen, Olga P, Fiorini, Giulia, Saracino, Ilaria Maria, Pavoni, Matteo, Romano, Marco, Gravina, Antonietta Gerarda, Granata, Lucia, Pellicano, Rinaldo, Gasbarrini, Antonio, Di Leo, Alfredo, Losurdo, Giuseppe, Franceschi, Francesco, Nardone, Gerardo, Rocco, Alba, Dore, Maria Pina, Farinati, Fabio, Ghisa, Matteo, Bellini, Massimo, Holton, John, Puig, Ignasi, Vaira, Dino, Borghi, Claudio, Mégraud, Franci, O'Morain, Colm, Gisbert, Javier P, Gatta, Luigi, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), and Franceschi, Francesco (ORCID:0000-0001-6266-445X)
Abstract: Background and AimsThe optimal management of naive and not naive Helicobacter pylori patients remains unclear. Therefore, it is essential to evaluate whether the actual clinical practice mirrors the indications suggested by the guidelines. This study aimed to assess the effectiveness and the safety of the empirical first- and second-line treatments prescribed to patients enroled at Italian centres participating in the European Registry on H. pylori Management (Hp-EuReg). MethodsThe Hp-EuReg is an international multicentre prospective non-interventional registry starting in 2013 aiming to evaluate the management of H. pylori infection by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables assessed included demographics, previous eradication attempts, treatment regimen, effectiveness, and tolerance. ResultsOverall, 3723 patients from 2013 to February 2021 were included: 2996 and 727 received an empirical first- and second-line treatment, respectively. According to the modified ITT analysis, among the first-line regimens, only the bismuth quadruple therapy with three-in-one-single capsule (BQT-TSC), the concomitant, and the sequential treatment - all lasting 10 days - achieved an eradication rate >90%. Among the second-line regimens, only the 10-day BQT-TSC reported an effectiveness >90%. High-dose PPI twice daily also significantly increased the effectiveness of some therapies. The BQT-TSC was the regimen with the highest incidence of adverse events. ConclusionsOnly quadruple therapies lasting at least 10 days achieved over 90% eradication rates among the empirical first- and second-line regimens. It remains unclear whether high-dose PPI twice daily can improve the efficacy of quadruple treatment.
Published: 2023

18. Role of proton pump inhibitors dosage and duration in Helicobacter pylorieradication treatment: Results from the European Registry on H. pylorimanagement

Author: Pabón‐Carrasco, Manuel, Keco‐Huerga, Alma, Castro‐Fernández, Manuel, Saracino, Ilaria Maria, Fiorini, Giulia, Vaira, Dino, Pérez‐Aísa, Ángeles, Tepes, Bojan, Jonaitis, Laimas, Voynovan, Irina, Lucendo, Alfredo J., Lanas, Ángel, Martínez‐Domínguez, Samuel J., Almajano, Enrique Alfaro, Rodrigo, Luis, Vologzanina, Ludmila, Brglez Jurecic, Natasa, Denkovski, Maja, Bujanda, Luis, Abdulkhakov, Rustam A., Huguet, Jose M., Fernández‐Salazar, Luis, Alcaide, Noelia, Velayos, Benito, Silkanovna Sarsenbaeva, Aiman, Zaytsev, Oleg, Ilchishina, Tatiana, Barrio, Jesús, Bakulin, Igor, Perona, Monica, Alekseenko, Sergey, Romano, Marco, Gravina, Antonietta G., Núñez, Óscar, Gómez Rodríguez, Blas José, Ledro‐Cano, Diego, Pellicano, Rinaldo, Bogomolov, Pavel, Domínguez‐Cajal, Manuel, Almela, Pedro, Gomez‐Camarero, Judith, Bordin, Dmitry S., Gasbarrini, Antonio, Kupčinskas, Juozas, Cano‐Català, Anna, Moreira, Leticia, Nyssen, Olga P., Mégraud, Francis, O’Morain, Colm, Gisbert, Javier P., Tejedor‐Tejada, Javier, Tarasova, Galina, Dekhnich, Natalia Nikolaevna, Di Leo, Alfredo, Losurdo, Giuseppe, Fernández‐Bermejo, Miguel, Iyo, Eduardo, Bermejo, Fernando, Algaba, Alicia, Grigorieva, Ludmila, Lamuela Calvo, Luis Javier, Jiménez, Itxaso, Starostin, Boris D., Baryshnikova, Natalia, Peña‐Negro, Luisa C., Planella, Montserrat, Ramirez, Consuelo, Bakanova, Natalia V., Farinati, Fabio, Ghisa, Matteo, Angueira, Teresa, Kononova, Alla, Campillo, Ana, Villarroya, Ramón Pajares, Gomez, Barbara, Belousova, Liya Nikolaevna, Compare, Debora, Alcedo, Javier, Burgos‐Santamaría, Diego, Rancel‐Medina, Francisco‐José, Pérez‐Martínez, Isabel, Maev, Igor, Andreev, Dmitrii, González‐Santiago, Jesús M., Segarra Ortega, José Xavier, Flores, Virginia, Cuadrado‐Lavín, Antonio, and Hernández, Luis
Abstract: Management of Helicobacter pylori(H. pylori) infection requires co‐treatment with proton pump inhibitors (PPIs) and the use of antibiotics to achieve successful eradication. To evaluate the role of dosage of PPIs and the duration of therapy in the effectiveness of H. pylorieradication treatments based on the ‘European Registry on Helicobacter pylorimanagement’ (Hp‐EuReg). Hp‐EuReg is a multicentre, prospective, non‐interventionist, international registry on the routine clinical practice of H. pylorimanagement by European gastroenterologists. All infected adult patients were systematically registered from 2013 to 2022. Overall, 36,579 patients from five countries with more than 1000 patients were analysed. Optimal (≥90%) first‐line‐modified intention‐to‐treat effectiveness was achieved with the following treatments: (1) 14‐day therapies with clarithromycin‐amoxicillin‐bismuth and metronidazole‐tetracycline‐bismuth, both independently of the PPI dose prescribed; (2) All 10‐day (except 10‐day standard triple therapy) and 14‐day therapies with high‐dose PPIs; and (3) 10‐day quadruple therapies with clarithromycin‐amoxicillin‐bismuth, metronidazole‐tetracycline‐bismuth, and clarithromycin‐amoxicillin‐metronidazole (sequential), all with standard‐dose PPIs. In first‐line treatment, optimal effectiveness was obtained with high‐dose PPIs in all 14‐day treatments, in 10‐ and 14‐day bismuth quadruple therapies and in 10‐day sequential with standard‐dose PPIs. Optimal second‐line effectiveness was achieved with (1) metronidazole‐tetracycline‐bismuth quadruple therapy for 14‐ and 10 days with standard and high‐dose PPIs, respectively; and (2) levofloxacin‐amoxicillin triple therapy for 14 days with high‐dose PPIs. None of the 7‐day therapies in both treatment lines achieved optimal effectiveness. We recommend, in first‐line treatment, the use of high‐dose PPIs in 14‐day triple therapy and in 10‐or 14‐day quadruple concomitant therapy in first‐line treatment, while standard‐dose PPIs would be sufficient in 10‐day bismuth quadruple therapies. On the other hand, in second‐line treatment, high‐dose PPIs would be more beneficial in 14‐day triple therapy with levofloxacin and amoxicillin or in 10‐day bismuth quadruple therapy either as a three‐in‐one single capsule or in the traditional scheme.
Published: 2024
Full Text: View/download PDF

19. Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on Helicobacter pylori Management (Hp-EuReg).

Author: Pérez-Aisa, Ángeles, Nyssen, Olga P., Keco-Huerga, Alma, Rodrigo, Luís, Lucendo, Alfredo J., Gomez-Rodriguez, Blas J., Ortuño, Juan, Perona, Mónica, María Huguet, José, Núñez, Oscar, Fernandez-Salazar, Luis, Barrio, Jesus, Lanas, Angel, Iyo, Eduardo, Mata Romero, Pilar, Fernández-Bermejo, Miguel, Gomez, Barbara, Garre, Ana, Gomez-Camarero, Judith, and Lamuela, Luis Javier
Subjects: HELICOBACTER pylori infections, HELICOBACTER pylori, DUODENAL ulcers, SCHEDULING, BISMUTH, DRUG resistance in bacteria
Published: 2023
Full Text: View/download PDF

20. 131 - PAUTAS Y EFECTIVIDAD DE LAS TERAPIAS CUÁDRUPLES CON BISMUTO EN EUROPA: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author: Calvet, Xavier, primary, Gené, Emili, additional, Olmedo, Llum, additional, Bordin, Dmitry, additional, García-Morales, Natalia, additional, Hernández, Luis, additional, Gridnyev, Oleksiy, additional, Kupinskas, Juozas, additional, Gasbarrini, Antonio, additional, Boltin, Doron, additional, Babayeva, Gulustan, additional, Pinto, Ricardo Marcos, additional, Tepes, Bojan, additional, Buzas, Gyorgy M, additional, Papp, Veronika, additional, Simsek, Halis, additional, Cano-Català, Anna, additional, Moreira, Leticia, additional, Puig, Ignasi, additional, Nyssen, Olga P., additional, Mégraud, Francis, additional, O’Morain, Colm, additional, and Gisbert, Javier P., additional
Published: 2023
Full Text: View/download PDF

21. 138 - EFECTIVIDAD EN PRIMERA LÍNEA DE TRATAMIENTO FRENTE A HELICOBACTER PYLORI: SUBANÁLISIS DE LOS DATOS ESPAÑOLES DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR H. PYLORI (HPEUREG)

Author: Hernández, Luis, primary, Pérez-Aisa, Maria Ángeles, additional, Domínguez, Samuel Jesús Martínez-, additional, Pabón-Carrasco, Manuel, additional, Bujanda, Luis, additional, Lucendo, Alfredo, additional, Rodrigo, Luis, additional, Garre, Ana, additional, Huguet, Jose María, additional, Alcaide, Noelia, additional, Perona, Mónica, additional, Barrio, Jesús, additional, Núñez, Óscar, additional, Tejada, Javier Tejedor, additional, Mata, Pilar, additional, Ledro, Diego, additional, Ortuño, Juan, additional, Cajal, Manuel Domínguez, additional, Ladrón, Gema, additional, Camarero, Judith Gómez, additional, Rodríguez, Blas José Gómez, additional, Nyssen, Olga P., additional, Megraud, Francis, additional, O’Morain, Colm, additional, and Gisbert, Javier P., additional
Published: 2023
Full Text: View/download PDF

22. 139 - EFECTIVIDAD EN SEGUNDA LÍNEA DE TRATAMIENTO FRENTE A HELICOBACTER PYLORI: SUBANÁLISIS DE LOS DATOS ESPAÑOLES DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR H. PYLORI (HPEUREG)

Author: Hernández, Luis, primary, Pérez-Aisa, Maria Ángeles, additional, Domínguez, Samuel Jesús Martínez-, additional, Pabón-Carrasco, Manuel, additional, Bujanda, Luis, additional, Lucendo, Alfredo, additional, Rodrigo, Luis, additional, Garre, Ana, additional, Huguet, Jose María, additional, Alcaide, Noelia, additional, Perona, Mónica, additional, Barrio, Jesús, additional, Núñez, Óscar, additional, Tejada, Javier Tejedor, additional, Mata, Pilar, additional, Ledro, Diego, additional, Ortuño, Juan, additional, Cajal, Manuel Domínguez, additional, Ladrón, Gema, additional, Camarero, Judith Gómez, additional, Rodríguez, Blas José Gómez, additional, Nyssen, Olga P., additional, Megraud, Francis, additional, O’Morain, Colm, additional, and Gisbert, Javier P., additional
Published: 2023
Full Text: View/download PDF

23. 134 - EFECTIVIDAD DE LA TERAPIA DE ERRADICACIÓN EMPÍRICA CON FURAZOLIDONA: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP- EUREG)

Author: Bordin, D.S., primary, Voynovan, I.N., additional, Sarsenbaeva, A.S., additional, Zaitsev, O.V., additional, Abdulkhakov, R.A., additional, Bakulina, N.V., additional, Bakulin, I.G., additional, Osipenko, M.F., additional, Livzan, M.A., additional, Alekseenko, S.A., additional, Tarasova, L.V., additional, Tarasova, G.N., additional, Bogomolov, P.O., additional, Maev, I.V., additional, Andreev, D.N., additional, Abdulhakov, S.R., additional, Starostin, B.D., additional, Bakanova, N.V., additional, Kononova, A.G., additional, Kolbasnikov, S.V., additional, E.L, Bueverova, additional, Cano-Català, Anna, additional, Moreira, Leticia, additional, Mégraud, Francis, additional, O’Morain, Colm, additional, Nyssen, Olga P., additional, and Gisbert, Javier P., additional
Published: 2023
Full Text: View/download PDF

24. 128 - TENDENCIAS TEMPORALES DE PRESCRIPCIÓN DE TRATAMIENTOS ERRADICADORES Y DE SU EFECTIVIDAD EN PACIENTES NAÏVE EN ESPAÑA ENTRE 2013 Y 2022: 10 AÑOS DE EXPERIENCIA DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR H. PYLORI (HP-EUREG)

Author: Hernández, Luis, primary, Pérez-Aisa, Maria Ángeles, additional, Domínguez, Samuel Jesús Martínez-, additional, Pabón-Carrasco, Manuel, additional, Bujanda, Luis, additional, Lucendo, Alfredo, additional, Rodrigo, Luis, additional, Garre, Ana, additional, Huguet, Jose María, additional, Alcaide, Noelia, additional, Perona, Mónica, additional, Barrio, Jesús, additional, Núñez, Óscar, additional, Tejada, Javier Tejedor, additional, Mata, Pilar, additional, Ledro, Diego, additional, Ortuño, Juan, additional, Cajal, Manuel Dominguez, additional, Ladrón, Gema, additional, Camarero, Judith Gómez, additional, Rodríguez, Blas José Gómez, additional, Nyssen, Olga P., additional, Megraud, Francis, additional, O’Morain, Colm, additional, and Gisbert, Javier P., additional
Published: 2023
Full Text: View/download PDF

25. 129 - EFECTIVIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI EN FUNCIÓN DE LAS RESISTENCIAS ANTIBIÓTICAS: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author: Bujanda, Luis, primary, Nyssen, Olga P., additional, Ramos, June, additional, Bordin, Dmitry S., additional, Tepes, Bojan, additional, Pérez-Aisa, Angeles, additional, Pavoni, Matteo, additional, Castro-Fernández, Manuel, additional, Lerang, Frode, additional, Leja, Marcis, additional, Rodrigo, Luis, additional, Rokkas, Theodore, additional, Kupcinskas, Juozas, additional, Jonaitis, Laimas, additional, Shvets, Oleg, additional, Gasbarrini, Antonio, additional, Simsek, Halis, additional, Phull, Perminder S, additional, Buzás, Gyorgiy Miklós, additional, Machado, Jose C., additional, Boltin, Doron, additional, Boyanova, Lyudmila, additional, Tonkic, Ante, additional, Marlicz, Wojciech, additional, Venerito, Marino, additional, Vologzanina, Ludmila, additional, Fadieienko, Galina D, additional, Fiorini, Giulia, additional, Resina, Elena, additional, Muñoz, Raquel, additional, Cano-Catalá, Anna, additional, Puig, Ignasi, additional, García-Morales, Natalia, additional, Hernández, Luis, additional, Moreira, Leticia, additional, Megraud, Francis, additional, Morain, Colm O, additional, and Gisbert, Javier P., additional
Published: 2023
Full Text: View/download PDF

26. PAPEL DEL USO DE PROBIÓTICOS EN LA EFECTIVIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author: Casas, Diego, primary, Alcedo, Javier, additional, Lafuente, Miguel, additional, López, F. Javier, additional, Pérez-Aisa, Angeles, additional, Pavoni, Matteo, additional, Saracino, Ilaria Maria, additional, Tepes, Bojan, additional, Jonaitis, Laimas, additional, Castro-Fernández, Manuel, additional, Carrasco, Manuel Pabón, additional, Huerga, Alma Keco-, additional, Voynovan, Irina, additional, Bujanda, Luis, additional, Lucendo, Alfredo J., additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Phull, Perminder S., additional, Rodrigo, Luis, additional, Lanas, Angel, additional, Martínez-Domínguez, Samuel J., additional, Alfaro, Enrique, additional, Fadieienko, Galina D, additional, Huguet, José M., additional, Bordin, Dmitry S., additional, Gasbarrini, Antonio, additional, Kupcinskas, Juozas, additional, Babayeva, Gülüstan, additional, Gridnyev, Oleksiy, additional, Leja, Mrcis, additional, Rokkas, Theodore, additional, Marcos-Pinto, Ricardo, additional, Lerang, Frode, additional, Boltin, Doron, additional, Papp, Veronika, additional, Tonki, Ante, additional, Smith, Sinead M., additional, Simsek, Halis, additional, Venerito, Marino, additional, Boyanova, Lyudmila, additional, Milivojevic, Vladimir, additional, Kunovsky, Lumir, additional, Matysiak-Budnik, Tamara, additional, Marlicz, Wojciech, additional, Doulberis, Michael, additional, Cano-Català, Anna, additional, Hernández, Luis, additional, Moreira, Leticia, additional, Nyssen, Olga P., additional, Megraud, Francis, additional, Morain, Colm O., additional, and Gisbert, Javier P., additional
Published: 2023
Full Text: View/download PDF

27. 135 - TENDENCIAS DE PRESCRIPCIÓN DE TRATAMIENTOS ERRADICADORES Y DE SU EFECTIVIDAD EN PACIENTES NAÏVE A LO LARGO DE 10 AÑOS (2013-2022) EN EUROPA: DATOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author: Nyssen, Olga P., primary, Jonaitis, Laimas, additional, Pérez-Aísa, Ángeles, additional, Vaira, Dino, additional, Fiorini, Giulia, additional, Saracino, Ilaria Maria, additional, Tepes, Bojan, additional, Bordin, Dmitry, additional, Huerga, Alma Keco-, additional, Castro-Fernández, Manuel, additional, Lucendo, Alfredo, additional, Vologzhanina, Liudmila, additional, Bujanda, Luis, additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Lanas, Angel, additional, Martínez-Dominguez, Samuel, additional, Alfaro, Enrique, additional, Leja, Marcis, additional, Bumane, Renate, additional, Mammadov, Emin, additional, Babayeva, Gulustan, additional, Mahmudov, Umud, additional, Caldas, María, additional, Rodrigo, Luis, additional, Lerang, Frode, additional, Fadieienko, Galyna, additional, Abdulkhakov, Rustam, additional, Malavés, Jose María Huguet, additional, Zaytsev, Oleg, additional, Ilchishina, Tatiana, additional, Fernández-Salazar, Luis, additional, Alcaide, Noelia, additional, Velayos, Benito, additional, Sarsenbaeva, Aiman Silkanovna, additional, Bakulin, Igor, additional, Gravina, Antonietta G., additional, Romano, Marco, additional, Perona, Mónica, additional, Alekseenko, Sergey, additional, Barrio, Jesús, additional, Areia, Miguel, additional, Nuñez, Óscar, additional, Bogomolov, Pavel, additional, Rodríguez, Blas José Gómez, additional, Cajal, Manuel Dominguez-, additional, Camarero, Judith Gomez, additional, Moreno, Manuel Jiménez, additional, Georgopoulos, Sotirios, additional, Notari, Pedro Almela, additional, Tonkic, Ante, additional, Pellicano, Rinaldo, additional, Simsek, Halis, additional, Kunovský, Lumír, additional, Gasbarrini, Antonio, additional, Bote, Jose Maria Botargues, additional, Buzas, Gyorgy M, additional, Fernández-Bermejo, Miguel, additional, Phull, Perminder, additional, Venerito, Marino, additional, Malfertheiner, Peter, additional, Rosania, Rosa, additional, Link, Alexander, additional, Iyo, Eduardo, additional, Kupinskas, Juozas, additional, Shvets, Oleg, additional, Pinto, Ricardo Marcos, additional, Rokkas, Theodore, additional, Simsek, Ilkay, additional, Smith, Sinead, additional, Boltin, Doron, additional, Lamarque, Dominique, additional, Dobru, Daniela, additional, Marlicz, Wojciech, additional, Milivojevic, Vladimir, additional, Boyanova, Lyudmila, additional, Lamy, Vincent, additional, Doulberis, Michael, additional, Bytzer, Peter, additional, Capelle, Lisette, additional, Gridnyev, Oleksiy, additional, Ristimaki, Ari, additional, Cano-Català, Anna, additional, Puig, Ignasi, additional, Mégraud, Francis, additional, O’Morain, Colm, additional, and Gisbert, Javier P., additional
Published: 2023
Full Text: View/download PDF

28. 130 - COMPARACIÓN DE LA EFECTIVIDAD DE LOS TRATAMIENTOS ERRADICADORES MÁS FRECUENTES ENTRE LAS POBLACIONES MÁS MAYORES Y MÁS JÓVENES DE EUROPA: DATOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author: Jonaitis, Paulius, primary, Nyssen, Olga P., additional, Saracino, Ilaria Maria, additional, Fiorini, Giulia, additional, Vaira, Dino, additional, Pérez-Aísa, Ángeles, additional, Tepes, Bojan, additional, Castro-Fernández, M., additional, Pabón-Carrasco, Manuel, additional, Keco-Huerga, Alma, additional, Voynovan, Irina, additional, Lucendo, Alfredo J, additional, Lanas, Ángel, additional, Martínez-Domínguez, Samuel J, additional, Almajano, Enrique Alfaro, additional, Rodrigo, Luis, additional, Vologzanina, Ludmila, additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Bujanda, Luis, additional, Mahmudov, Umud, additional, Leja, Mrcis, additional, Lerang, Frode, additional, Babayeva, Gülüstan, additional, Bordin, Dmitry S., additional, Gasbarrini, Antonio, additional, Kupcinskas, Juozas, additional, Gridnyev, Oleksiy, additional, Rokkas, Theodore, additional, Marcos-Pinto, Ricardo, additional, Phull, Perminder S., additional, Smith, Sinead M., additional, Tonki, Ante, additional, Boltin, Doron, additional, Buzás, György Miklós, additional, Kunovský, Lumír, additional, imek, Halis, additional, Matysiak-Budnik, Tamara, additional, Milivojevic, Vladimir, additional, Marlicz, Wojciech, additional, Venerito, Marino, additional, Boyanova, Lyudmila, additional, Doulberis, Michael, additional, Capelle, Lisette G., additional, Cano-Català, Anna, additional, Moreira, Leticia, additional, Mégraud, Francis, additional, O’Morain, Colm, additional, Gisbert, Javier P., additional, and Jonaitis, Laimas, additional
Published: 2023
Full Text: View/download PDF

29. 140 - TRATAMIENTO ERRADICADOR DE SEXTA LÍNEA FRENTE A HELICOBACTER PYLORI: DATOS PRELIMINARES DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author: Nyssen, Olga P., primary, Garre, Ana, additional, Fiorini, Giulia, additional, Saracino, Ilaria Maria, additional, Pavoni, Matteo, additional, Vaira, Dino, additional, Phull, Perminder, additional, Beales, Ian, additional, Gasbarrini, Antonio, additional, Cano-Català, Anna, additional, Moreira, Leticia, additional, Mégraud, Francis, additional, O’Morain, Colm, additional, and Gisbert, Javier P., additional
Published: 2023
Full Text: View/download PDF

30. 127 - IMPACTO DEL USO DE PROBIÓTICOS EN LA SEGURIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author: Casas, Diego, primary, Alcedo, Javier, additional, Lafuente, Miguel, additional, López, F. Javier, additional, Pérez-Aisa, Angeles, additional, Pavoni, Matteo, additional, Saracino, Ilaria Maria, additional, Tepes, Bojan, additional, Jonaitis, Laimas, additional, Castro-Fernández, Manuel, additional, Pabón-Carrasco, Manuel, additional, Keco-Huerga, Alma, additional, Voynovan, Irina, additional, Bujanda, Luis, additional, Lucendo, Alfredo J., additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Phull, Perminder S., additional, Rodrigo, Luis, additional, Lanas, Angel, additional, Martínez-Domínguez, Samuel J., additional, Alfaro, Enrique, additional, Fadieienko, Galina D., additional, Huguet, Jose M., additional, Bordin, Dmitry S., additional, Gasbarrini, Antonio, additional, Kupcinskas, Juozas, additional, Babayeva, Gülüstan, additional, Gridnyev, Oleksiy, additional, Leja, Mrcis, additional, Rokkas, Theodore, additional, Marcos-Pinto, Ricardo, additional, Lerang, Frode, additional, Boltin, Doron, additional, Papp, Veronika, additional, Tonki, Ante, additional, Smith, Sinead M., additional, Simsek, Halis, additional, Venerito, Marino, additional, Boyanova, Lyudmila, additional, Milivojevic, Vladimir, additional, Kunovsky, Lumir, additional, Matysiak-Budnik, Tamara, additional, Marlicz, Wojciech, additional, Doulberis, Michael, additional, Cano-Català, Anna, additional, Hernández, Luis, additional, Moreira, Leticia, additional, Nyssen, Olga P., additional, Megraud, Francis, additional, Morain, Colm O., additional, and Gisbert, Javier P., additional
Published: 2023
Full Text: View/download PDF

31. 123 - OPTIMIZACIÓN DE LA DOSIS DE LOS INHIBIDORES DE LA BOMBA DE PROTONES EN LOS TRATAMIENTOS ERRADICADORES DE PRIMERA Y SEGUNDA LÍNEA FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author: Keco-Huerga, Alma, primary, Pabón-Carrasco, Manuel, additional, Castro-Fernández, Manuel, additional, Saracino, Ilaria Maria, additional, Fiorini, Giulia, additional, Vaira, Dino, additional, Pérez-Aísa, Ángeles, additional, Tepes, Bojan, additional, Jonaitis, Laimas, additional, Voynovan, Irina, additional, Lucendo, Alfredo J, additional, Lanas, Ángel, additional, Martínez-Domínguez, Samuel J, additional, Almajano, Enrique Alfaro, additional, Rodrigo, Luis, additional, Vologzanina, Ludmila, additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Bujanda, Luis, additional, Abdulkhakov, Rustam A, additional, Huguet, José M., additional, Salazar, L. Fernández, additional, Alcaide, Noelia, additional, Velayos, Benito, additional, Sarsenbaeva, Aiman Silkanovna, additional, Zaytsev, Oleg, additional, Ilchishina, Tatiana, additional, Barrio, Jesús, additional, Bakulin, Igor, additional, Perona, Monica, additional, Alekseenko, Sergey, additional, Romano, Marco, additional, Gravina, Antonietta G., additional, Núñez, Óscar, additional, Rodríguez, Blas José Gómez, additional, Ledro-Cano, Diego, additional, Pellicano, Rinaldo, additional, Bogomolov, Pavel, additional, Domínguez-Cajal, Manuel, additional, Almela, Pedro, additional, Gomez-Camarero, Judith, additional, Bordin, Dmitry S., additional, Gasbarrini, Antonio, additional, Kupinskas, Juozas, additional, Cano-Català, Anna, additional, Moreira, Leticia, additional, Nyssen, Olga P., additional, Mégraud, Francis, additional, O’Morain, Colm, additional, and Gisbert, Javier P., additional
Published: 2023
Full Text: View/download PDF

32. LA ADMINISTRACIÓN DE LA TERAPIA CUÁDRUPLE CON BISMUTO EN CÁPSULA ÚNICA TRES VECES AL DÍA AUMENTA LA EFICACIA EN COMPARACIÓN CON LA PAUTA CONVENCIONAL DE CUATRO DOSIS DIARIAS: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author: Pérez-Aísa, Ángeles, primary, Nyssen, Olga P., additional, Keco-Huerga, Alma, additional, Rodrigo, Luis, additional, Lucendo, Alfredo J, additional, Rodríguez, Blas José Gómez, additional, Ortuño, Juan, additional, Perona, Mónica, additional, Huguet, José M., additional, Núñez, Óscar, additional, Fernández-Salazar, Luis, additional, Barrio, Jesús, additional, Lanas, Ángel, additional, Iyo, Eduardo, additional, Romero, Pilar Mata, additional, Bermejo, Miguel Fernández-, additional, Gomez, Barbara, additional, Garre, Ana, additional, Gomez-Camarero, Judith, additional, Lamuela, Luis Javier, additional, Campillo, Ana, additional, de la Peña-Negro, Luisa C, additional, Dominguez-Cajal, Manuel, additional, Bujanda, Luis, additional, Burgos-Santamaria, Diego, additional, Bermejo, Fernando, additional, González-Carrera, Víctor, additional, Pajares, Ramón, additional, Notari, Pedro Almela, additional, Tejedor-Tejada, Javier, additional, Planella, Montserrat, additional, Jiménez, Itxaso, additional, Lázaro, Yolanda Arguedas, additional, Cuadrado-Lavín, Antonio, additional, Pérez-Martínez, Isabel, additional, Amorena, Edurne, additional, Santiago, Jesús M González-, additional, Angueira, Teresa, additional, Flores, Virginia, additional, Martínez-Domínguez, Samuel Jesús, additional, Pabón-Carrasco, Manuel, additional, Velayos, Benito, additional, Algaba, Alicia, additional, Ramírez, Consuelo, additional, Almajano, Enrique Alfaro, additional, Castro-Fernández, Manuel, additional, Alcaide, Noelia, additional, Segura, Patricia Sanz, additional, Cano-Català, Anna, additional, Morales, Natalia García-, additional, Moreira, Leticia, additional, Mégraud, Francis, additional, O’Morain, Colm, additional, Calvet, Xavier, additional, and Gisbert, Javier P., additional
Published: 2023
Full Text: View/download PDF

33. 133 - PATRÓN DE PRESCRIPCIÓN DE PROBIÓTICOS ADYUVANTES A LA TERAPIA ERRADICADORA FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author: Casas, Diego, primary, Alcedo, Javier, additional, Lafuente, Miguel, additional, López, F. Javier, additional, Pérez-Aisa, Angeles, additional, Pavoni, Matteo, additional, Saracino, Ilaria Maria, additional, Tepes, Bojan, additional, Jonaitis, Laimas, additional, Castro-Fernández, Manuel, additional, Pabón-Carrasco, Manuel, additional, Keco-Huerga, Alma, additional, Voynovan, Irina, additional, Bujanda, Luis, additional, Lucendo, Alfredo J., additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Phull, Perminder S., additional, Rodrigo, Luis, additional, Lanas, Angel, additional, Martínez-Domínguez, Samuel J., additional, Alfaro, Enrique, additional, Fadieienko, Galina D, additional, Huguet, José M., additional, Bordin, Dmitry S., additional, Gasbarrini, Antonio, additional, Kupcinskas, Juozas, additional, Babayeva, Gülüstan, additional, Gridnyev, Oleksiy, additional, Leja, Mrcis, additional, Rokkas, Theodore, additional, Marcos-Pinto, Ricardo, additional, Lerang, Frode, additional, Boltin, Doron, additional, Papp, Veronika, additional, Tonki, Ante, additional, Smith, Sinead M., additional, Simsek, Halis, additional, Venerito, Marino, additional, Boyanova, Lyudmila, additional, Milivojevic, Vladimir, additional, Kunovsky, Lumir, additional, Matysiak-Budnik, Tamara, additional, Marlicz, Wojciech, additional, Doulberis, Michael, additional, Cano-Català, Anna, additional, Hernández, Luis, additional, Moreira, Leticia, additional, Nyssen, Olga P., additional, Megraud, Francis, additional, Morain, Colm O., additional, and Gisbert, Javier P., additional
Published: 2023
Full Text: View/download PDF

34. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis

Author: Marin, Alicia C., Nyssen, Olga P., McNicholl, Adrian G., and Gisbert, Javier P.
Published: 2017
Full Text: View/download PDF

35. Effectiveness of first and second‐line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management

Author: Gatta, Luigi, primary, Nyssen, Olga P., additional, Fiorini, Giulia, additional, Saracino, Ilaria Maria, additional, Pavoni, Matteo, additional, Romano, Marco, additional, Gravina, Antonietta Gerarda, additional, Granata, Lucia, additional, Pellicano, Rinaldo, additional, Gasbarrini, Antonio, additional, Di Leo, Alfredo, additional, Losurdo, Giuseppe, additional, Franceschi, Francesco, additional, Nardone, Gerardo, additional, Rocco, Alba, additional, Dore, Maria Pina, additional, Farinati, Fabio, additional, Ghisa, Matteo, additional, Bellini, Massimo, additional, Holton, John, additional, Puig, Ignasi, additional, Vaira, Dino, additional, Borghi, Claudio, additional, Mégraud, Francis, additional, O'Morain, Colm, additional, and Gisbert, Javier P., additional
Published: 2022
Full Text: View/download PDF

36. Empirical rescue treatment ofHelicobacter pyloriinfection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry onH. pylorimanagement (Hp-EuReg)

Author: Burgos-Santamaría, Diego, primary, Nyssen, Olga P, additional, Gasbarrini, Antonio, additional, Vaira, Dino, additional, Pérez-Aisa, Ángeles, additional, Rodrigo, Luís, additional, Pellicano, Rinaldo, additional, Keco-Huerga, Alma, additional, Pabón-Carrasco, Manuel, additional, Castro-Fernandez, Manuel, additional, Boltin, Doron, additional, Barrio, Jesus, additional, Phull, Perminder, additional, Kupcinskas, Juozas, additional, Jonaitis, Laimas, additional, Ortiz-Polo, Inmaculada, additional, Tepes, Bojan, additional, Lucendo, Alfredo J, additional, Huguet, José María, additional, Areia, Miguel, additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Bujanda, Luís, additional, Ramos-San Román, June, additional, Cuadrado-Lavín, Antonio, additional, Gomez-Camarero, Judith, additional, Jiménez Moreno, Manuel Alfonso, additional, Lanas, Angel, additional, Martinez-Dominguez, Samuel Jesús, additional, Alfaro, Enrique, additional, Marcos-Pinto, Ricardo, additional, Milivojevic, Vladimir, additional, Rokkas, Theodore, additional, Leja, Marcis, additional, Smith, Sinead, additional, Tonkić, Ante, additional, Buzás, György Miklós, additional, Doulberis, Michael, additional, Venerito, Marino, additional, Lerang, Frode, additional, Bordin, Dmitry S, additional, Lamy, Vincent, additional, Capelle, Lisette G, additional, Marlicz, Wojciech, additional, Dobru, Daniela, additional, Gridnyev, Oleksiy, additional, Puig, Ignasi, additional, Mégraud, Francis, additional, O'Morain, Colm, additional, and Gisbert, Javier P, additional
Published: 2022
Full Text: View/download PDF

37. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

Author: Nyssen, Olga P., primary, Vaira, Dino, additional, Pérez Aísa, Ángeles, additional, Rodrigo, Luis, additional, Castro-Fernandez, Manuel, additional, Jonaitis, Laimas, additional, Tepes, Bojan, additional, Vologzhanina, Liudmila, additional, Caldas, María, additional, Lanas, Angel, additional, Lucendo, Alfredo J., additional, Bujanda, Luis, additional, Ortuño, Juan, additional, Barrio, Jesús, additional, Huguet, Jose M., additional, Voynovan, Irina, additional, Lasala, Jorge Perez, additional, Sarsenbaeva, Aiman Silkanovna, additional, Fernandez-Salazar, Luis, additional, Molina-Infante, Javier, additional, Jurecic, Natasa Brglez, additional, Areia, Miguel, additional, Gasbarrini, Antonio, additional, Kupčinskas, Juozas, additional, Bordin, Dmitry, additional, Marcos-Pinto, Ricardo, additional, Lerang, Frode, additional, Leja, Marcis, additional, Buzas, Gyorgy M., additional, Niv, Yaron, additional, Rokkas, Theodore, additional, Phull, Perminder, additional, Smith, Sinead, additional, Shvets, Oleg, additional, Venerito, Marino, additional, Milivojevic, Vladimir, additional, Simsek, Ilkay, additional, Lamy, Vincent, additional, Bytzer, Peter, additional, Boyanova, Lyudmila, additional, Kunovský, Lumír, additional, Beglinger, Christoph, additional, Doulberis, Michael, additional, Marlicz, Wojciech, additional, Goldis, Adrian, additional, Tonkić, Ante, additional, Capelle, Lisette, additional, Puig, Ignasi, additional, Megraud, Francis, additional, Morain, Colm O’, additional, Gisbert, Javier P., additional, Fiorinni, Giulia, additional, Saracino, Ilaria Maria, additional, Carrasco, Manuel Pabon, additional, Huerga, Alma Keco, additional, Almajano, Enrique Alfaro, additional, Martinez Dominguez, Samuel Jesus, additional, Galan, Horacio Alonso, additional, Velayos, Benito, additional, Sadornil, Carmen Dueñas, additional, Botargues Bote, Jose Maria, additional, Gonzalez-Cordero, Pedro Luis, additional, Gomez Rodriguez, Blas Jose, additional, Pellicano, Rinaldo, additional, Nuñez, Óscar, additional, Franceschi, Francesco, additional, Alekseenko, Sergey, additional, Perona, Monica, additional, Abdulkhakov, Rustam, additional, Dominguez-Cajal, Manuel, additional, Notari, Pedro Almela, additional, Camarero, Judith Gomez, additional, Moreno, Manuel Jimenez, additional, Algaba, Alicia, additional, Bermejo, Fernando, additional, Tejada, Javier Tejedor, additional, Susanibar, Elida Oblitas, additional, Boltin, Doron, additional, Georgopoulos, Sotirios, additional, OMorain, Colm, additional, Qasim, Asghar, additional, Beales, Ian, additional, Bakulina, Natalia, additional, Fadeenko, Galina, additional, Malfertheiner, Peter, additional, Rosania, Rosa, additional, Ilchishina, Tatiana, additional, Bogomolov, Pavel, additional, Bakulin, Igor, additional, Zaytsev, Oleg, additional, Gravina, Antonietta Gerarda, additional, Romano, Marco, additional, Di Leo, Alfredo, additional, Losurdo, Giuseppe, additional, Grigorieva, Ludmila, additional, Guillena, Pedro Delgado, additional, Marusic, Marinko, additional, Jurcic, Dragan, additional, Dekhnich, Natalia Nikolaevna, additional, Iyo, Eduardo, additional, de la Peña Negro, Luisa Carmen, additional, Baryshnikova, Natalia, additional, Bakanova, Natalia, additional, Simsek, Halis, additional, Simsek, Cem, additional, Gridnyev, Oleksiy, additional, Fernandez-Bermejo, Miguel, additional, Angueira, Teresa, additional, Ruiz-Zorrilla Lopez, Rafael, additional, Gomez, Barbara, additional, Kovacheva-Slavova, Mila, additional, Lahat, Adi, additional, Alcedo, Javier, additional, Campillo, Ana, additional, Belousova, Liya Nikolaevna, additional, Villarroya, Ramon Pajares, additional, Ljubicic, Neven, additional, Nikolic, Marko, additional, González-Santiago, Jesús M., additional, Santamaría, Diego Burgos, additional, Pakhomova, Anna, additional, Sekulic-Spasic, Izabela, additional, Ghisa, Matteo, additional, Farinati, Fabio, additional, Sagdati, Sabir Irfan, additional, Panic, Nikola, additional, Heluwaert, Frederic, additional, Amorena, Edurne, additional, Moreira, Leticia, additional, Esparrach, Gloria Fernandez, additional, Plotnikova, Ekaterina Yuryevna, additional, Kukla, Michal, additional, Kamburov, Victor, additional, Lamuela Calvo, Luis Javier, additional, Rankovic, Ivan, additional, Lavín, Antonio Cuadrado, additional, Lazaro, Yolanda Arguedas, additional, Carrera Agnieszka Dobrowolska, Victor Gonzalez, additional, Eder, Piotr, additional, and Kononova, Alla, additional
Published: 2022
Full Text: View/download PDF

38. Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013–2022: Data from the European Registry on H. pylori Management (Hp-EuReg).

Author: Nyssen, Olga P., Pratesi, Pietro, Spínola, Miguel A., Jonaitis, Laimas, Pérez-Aísa, Ángeles, Vaira, Dino, Saracino, Ilaria Maria, Pavoni, Matteo, Fiorini, Giulia, Tepes, Bojan, Bordin, Dmitry S., Voynovan, Irina, Lanas, Ángel, Martínez-Domínguez, Samuel J., Alfaro, Enrique, Bujanda, Luis, Pabón-Carrasco, Manuel, Hernández, Luis, Gasbarrini, Antonio, and Kupcinskas, Juozas
Subjects: HELICOBACTER pylori, MACHINE learning, HELICOBACTER pylori infections, PHENOTYPES, TREATMENT effectiveness, CLUSTER analysis (Statistics)
Abstract: The segmentation of patients into homogeneous groups could help to improve eradication therapy effectiveness. Our aim was to determine the most important treatment strategies used in Europe, to evaluate first-line treatment effectiveness according to year and country. Data collection: All first-line empirical treatments registered at AEGREDCap in the European Registry on Helicobacter pylori management (Hp-EuReg) from June 2013 to November 2022. A Boruta method determined the "most important" variables related to treatment effectiveness. Data clustering was performed through multi-correspondence analysis of the resulting six most important variables for every year in the 2013–2022 period. Based on 35,852 patients, the average overall treatment effectiveness increased from 87% in 2013 to 93% in 2022. The lowest effectiveness (80%) was obtained in 2016 in cluster #3 encompassing Slovenia, Lithuania, Latvia, and Russia, treated with 7-day triple therapy with amoxicillin–clarithromycin (92% of cases). The highest effectiveness (95%) was achieved in 2022, mostly in Spain (81%), with the bismuth–quadruple therapy, including the single-capsule (64%) and the concomitant treatment with clarithromycin–amoxicillin–metronidazole/tinidazole (34%) with 10 (69%) and 14 (32%) days. Cluster analysis allowed for the identification of patients in homogeneous treatment groups assessing the effectiveness of different first-line treatments depending on therapy scheme, adherence, country, and prescription year. [ABSTRACT FROM AUTHOR]
Published: 2023
Full Text: View/download PDF

39. Evaluation of a New Monoclonal Chemiluminescent Immunoassay Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: A Spanish Multicentre Study

Author: Resina, Elena, primary, Donday, María G., additional, Martínez-Domínguez, Samuel J., additional, Laserna-Mendieta, Emilio José, additional, Lanas, Ángel, additional, Lucendo, Alfredo J., additional, Sánchez-Luengo, Marta, additional, Alcaide, Noelia, additional, Fernández-Salazar, Luis, additional, De La Peña-Negro, Luisa, additional, Bujanda, Luis, additional, Arbulo, Marta Gómez-Ruiz de, additional, Alcedo, Javier, additional, Pérez-Aísa, Ángeles, additional, Rodríguez, Raúl, additional, Hermida, Sandra, additional, Brenes, Yanire, additional, Nyssen, Olga P., additional, and Gisbert, Javier P., additional
Published: 2022
Full Text: View/download PDF

40. European Registry on Helicobacter pylori Management (Hp-EuReg): Most relevant results for clinical practice

Author: Nyssen, Olga P., primary, Moreira, Leticia, additional, García-Morales, Natalia, additional, Cano-Català, Anna, additional, Puig, Ignasi, additional, Mégraud, Francis, additional, O’Morain, Colm, additional, and Gisbert, Javier P., additional
Published: 2022
Full Text: View/download PDF

41. Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)

Author: Medicina, Medikuntza, Nyssen, Olga P., Vaira, Dino, Saracino, Ilaria Maria, Fiorini, Giulia, Caldas, María, Bujanda Fernández de Pierola, Luis, Pellicano, Rinaldo, Keco-Huerga, Alma, Pabón-Carrasco, Manuel, Oblitas Susanibar, Elida, Di Leo, Alfredo, Losurdo, Giuseppe, Pérez-Aísa, Ángeles, Gasbarrini, Antonio, Boltin, Doron, Smith, Sinead, Phull, Perminder, Rokkas, Theodore, Lamarque, Dominique, Cano-Català, Anna, Puig, Ignasi, Mégraud, Francis, O’Morain, Colm, Gisbert, Javier P, Medicina, Medikuntza, Nyssen, Olga P., Vaira, Dino, Saracino, Ilaria Maria, Fiorini, Giulia, Caldas, María, Bujanda Fernández de Pierola, Luis, Pellicano, Rinaldo, Keco-Huerga, Alma, Pabón-Carrasco, Manuel, Oblitas Susanibar, Elida, Di Leo, Alfredo, Losurdo, Giuseppe, Pérez-Aísa, Ángeles, Gasbarrini, Antonio, Boltin, Doron, Smith, Sinead, Phull, Perminder, Rokkas, Theodore, Lamarque, Dominique, Cano-Català, Anna, Puig, Ignasi, Mégraud, Francis, O’Morain, Colm, and Gisbert, Javier P
Abstract: Background: First-line Helicobacter pylori (H. pylori) treatments have been relatively well evaluated; however, it remains necessary to identify the most effective rescue treatments. Our aim was to assess the effectiveness and safety of H. pylori regimens containing rifabutin. METHODS: International multicentre prospective non-interventional European Registry on H. pylori Management (Hp-EuReg). Patients treated with rifabutin were registered in AEG-REDCap e-CRF from 2013 to 2021. Modified intention-to-treat and per-protocol analyses were performed. Data were subject to quality control. Results: Overall, 500 patients included in the Hp-EuReg were treated with rifabutin (mean age 52 years, 72% female, 63% with dyspepsia, 4% with peptic ulcer). Culture was performed in 63% of cases: dual resistance (to both clarithromycin and metronidazole) was reported in 46% of the cases, and triple resistance (to clarithromycin, metronidazole, and levofloxacin) in 39%. In 87% of cases rifabutin was utilised as part of a triple therapy together with amoxicillin and a proton-pump-inhibitor, and in an additional 6% of the patients, bismuth was added to this triple regimen. Rifabutin was mainly used in second-line (32%), third-line (25%), and fourth-line (27%) regimens, achieving overall 78%, 80% and 66% effectiveness by modified intention-to-treat, respectively. Compliance with treatment was 89%. At least one adverse event was registered in 26% of the patients (most frequently nausea), and one serious adverse event (0.2%) was reported in one patient with leukopenia and thrombocytopenia with fever requiring hospitalisation. Conclusion: Rifabutin-containing therapy represents an effective and safe strategy after one or even several failures of H. pylori eradication treatment.
Published: 2022

42. Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)

Author: Universidad de Sevilla. Departamento de Enfermería, Universidad de Sevilla. CTS1054: Intervenciones y cuidados de la salud. Cruz Roja., Nyssen, Olga P., Vaira, Dino, Saracino, Ilaria María, Fiorini, Giulia, Caldas, María, Bujanda, Luis, Pabón Carrasco, Manuel, Gisbert, Javier P., Universidad de Sevilla. Departamento de Enfermería, Universidad de Sevilla. CTS1054: Intervenciones y cuidados de la salud. Cruz Roja., Nyssen, Olga P., Vaira, Dino, Saracino, Ilaria María, Fiorini, Giulia, Caldas, María, Bujanda, Luis, Pabón Carrasco, Manuel, and Gisbert, Javier P.
Abstract: Background: First-line Helicobacter pylori (H. pylori) treatments have been relatively well evaluated; however, it remains necessary to identify the most effective rescue treatments. Our aim was to assess the effectiveness and safety of H. pylori regimens containing rifabutin. METHODS: International multicentre prospective non-interventional European Registry on H. pylori Management (Hp-EuReg). Patients treated with rifabutin were registered in AEG-REDCap e-CRF from 2013 to 2021. Modified intention-to-treat and per-protocol analyses were performed. Data were subject to quality control. Results: Overall, 500 patients included in the Hp-EuReg were treated with rifabutin (mean age 52 years, 72% female, 63% with dyspepsia, 4% with peptic ulcer). Culture was performed in 63% of cases: dual resistance (to both clarithromycin and metronidazole) was reported in 46% of the cases, and triple resistance (to clarithromycin, metronidazole, and levofloxacin) in 39%. In 87% of cases rifabutin was utilised as part of a triple therapy together with amoxicillin and a proton-pump inhibitor, and in an additional 6% of the patients, bismuth was added to this triple regimen. Rifabutin was mainly used in second-line (32%), third-line (25%), and fourth-line (27%) regimens, achieving overall 78%, 80% and 66% effectiveness by modified intention-to-treat, respectively. Compliance with treatment was 89%. At least one adverse event was registered in 26% of the patients (most frequently nausea), and one serious adverse event (0.2%) was reported in one patient with leukope nia and thrombocytopenia with fever requiring hospitalisation. Conclusion: Rifabutin-containing therapy represents an effective and safe strategy after one or even several failures of H. pylori eradication treatment.
Published: 2022

43. Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)

Author: Burgos-Santamaría, Diego, Nyssen, Olga P, Gasbarrini, Antonio, Vaira, Dino, Pérez-Aisa, Ángele, Rodrigo, Luí, Pellicano, Rinaldo, Keco-Huerga, Alma, Pabón-Carrasco, Manuel, Castro-Fernandez, Manuel, Boltin, Doron, Barrio, Jesu, Phull, Perminder, Kupcinskas, Juoza, Jonaitis, Laima, Ortiz-Polo, Inmaculada, Tepes, Bojan, Lucendo, Alfredo J, Huguet, José María, Areia, Miguel, Jurecic, Natasa Brglez, Denkovski, Maja, Bujanda, Luí, Ramos-San Román, June, Cuadrado-Lavín, Antonio, Gomez-Camarero, Judith, Jiménez Moreno, Manuel Alfonso, Lanas, Angel, Martinez-Dominguez, Samuel Jesú, Alfaro, Enrique, Marcos-Pinto, Ricardo, Milivojevic, Vladimir, Rokkas, Theodore, Leja, Marci, Smith, Sinead, Tonkić, Ante, Buzás, György Mikló, Doulberis, Michael, Venerito, Marino, Lerang, Frode, Bordin, Dmitry S, Lamy, Vincent, Capelle, Lisette G, Marlicz, Wojciech, Dobru, Daniela, Gridnyev, Oleksiy, Puig, Ignasi, Mégraud, Franci, O'Morain, Colm, Gisbert, Javier P, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Burgos-Santamaría, Diego, Nyssen, Olga P, Gasbarrini, Antonio, Vaira, Dino, Pérez-Aisa, Ángele, Rodrigo, Luí, Pellicano, Rinaldo, Keco-Huerga, Alma, Pabón-Carrasco, Manuel, Castro-Fernandez, Manuel, Boltin, Doron, Barrio, Jesu, Phull, Perminder, Kupcinskas, Juoza, Jonaitis, Laima, Ortiz-Polo, Inmaculada, Tepes, Bojan, Lucendo, Alfredo J, Huguet, José María, Areia, Miguel, Jurecic, Natasa Brglez, Denkovski, Maja, Bujanda, Luí, Ramos-San Román, June, Cuadrado-Lavín, Antonio, Gomez-Camarero, Judith, Jiménez Moreno, Manuel Alfonso, Lanas, Angel, Martinez-Dominguez, Samuel Jesú, Alfaro, Enrique, Marcos-Pinto, Ricardo, Milivojevic, Vladimir, Rokkas, Theodore, Leja, Marci, Smith, Sinead, Tonkić, Ante, Buzás, György Mikló, Doulberis, Michael, Venerito, Marino, Lerang, Frode, Bordin, Dmitry S, Lamy, Vincent, Capelle, Lisette G, Marlicz, Wojciech, Dobru, Daniela, Gridnyev, Oleksiy, Puig, Ignasi, Mégraud, Franci, O'Morain, Colm, Gisbert, Javier P, and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)
Abstract: Objective To evaluate the use, effectiveness and safety of Helicobacter pylori empirical rescue therapy in third and subsequent treatment lines in Europe. Design International, prospective, non-interventional registry of the clinical practice of European gastroenterologists. Data were collected and quality reviewed until October 2021 at Asociacion Espanola de Gastroenterologia-Research Electronic Data Capture. All cases with three or more empirical eradication attempts were assessed for effectiveness by modified intention-to-treat and per-protocol analysis. Results Overall, 2144 treatments were included: 1519, 439, 145 and 41 cases from third, fourth, fifth and sixth treatment lines, respectively. Sixty different therapies were used; the 15 most frequently prescribed encompassed > 90% of cases. Overall effectiveness remained < 90% in all therapies. Optimised treatments achieved a higher eradication rate than non-optimised (78% vs 67%, p < 0.0001). From 2017 to 2021, only 44% of treatments other than 10-day single-capsule therapy used high proton-pump inhibitor doses and lasted & GE;14 days. Quadruple therapy containing metronidazole, tetracycline and bismuth achieved optimal eradication rates only when prescribed as third-line treatment, either as 10-day single-capsule therapy (87%) or as 14-day traditional therapy with tetracycline hydrochloride (95%). Triple amoxicillin-levofloxacin therapy achieved 90% effectiveness in Eastern Europe only or when optimised. The overall incidence of adverse events was 31%. Conclusion Empirical rescue treatment in third and subsequent lines achieved suboptimal effectiveness in most European regions. Only quadruple bismuth-metronidazole-tetracycline (10-day single-capsule or 14-day traditional scheme) and triple amoxicillin-levofloxacin therapies reached acceptable outcomes in some settings. Compliance with empirical therapy optimisation principles is still poor 5 years after clinical practice guidelines update.
Published: 2022

44. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

Author: Nyssen, Olga P., Vaira, Dino, Pérez Aísa, Ángeles, Rodrigo, Luis, Castro-Fernandez, Manuel, Jonaitis, Laimas, Tepes, Bojan, Vologzhanina, Liudmila, Caldas, María, Lanas, Angel, Lucendo, Alfredo J., Bujanda, Luis, Ortuño, Juan, Barrio, Jesús, Huguet, Jose M., Voynovan, Irina, Lasala, Jorge Perez, Sarsenbaeva, Aiman Silkanovna, Fernandez-Salazar, Luis, Molina-Infante, Javier, Jurecic, Natasa Brglez, Areia, Miguel, Gasbarrini, Antonio, Kupčinskas, Juozas, Bordin, Dmitry, Marcos-Pinto, Ricardo, Lerang, Frode, Leja, Marcis, Buzas, Gyorgy M., Niv, Yaron, Rokkas, Theodore, Phull, Perminder, Smith, Sinead, Shvets, Oleg, Venerito, Marino, Milivojevic, Vladimir, Simsek, Ilkay, Lamy, Vincent, Bytzer, Peter, Boyanova, Lyudmila, Kunovský, Lumír, Beglinger, Christoph, Doulberis, Michael, Marlicz, Wojciech, Goldis, Adrian, Tonkić, Ante, Capelle, Lisette, Puig, Ignasi, Megraud, Francis, Morain, Colm O’, Nyssen, Olga P., Vaira, Dino, Pérez Aísa, Ángeles, Rodrigo, Luis, Castro-Fernandez, Manuel, Jonaitis, Laimas, Tepes, Bojan, Vologzhanina, Liudmila, Caldas, María, Lanas, Angel, Lucendo, Alfredo J., Bujanda, Luis, Ortuño, Juan, Barrio, Jesús, Huguet, Jose M., Voynovan, Irina, Lasala, Jorge Perez, Sarsenbaeva, Aiman Silkanovna, Fernandez-Salazar, Luis, Molina-Infante, Javier, Jurecic, Natasa Brglez, Areia, Miguel, Gasbarrini, Antonio, Kupčinskas, Juozas, Bordin, Dmitry, Marcos-Pinto, Ricardo, Lerang, Frode, Leja, Marcis, Buzas, Gyorgy M., Niv, Yaron, Rokkas, Theodore, Phull, Perminder, Smith, Sinead, Shvets, Oleg, Venerito, Marino, Milivojevic, Vladimir, Simsek, Ilkay, Lamy, Vincent, Bytzer, Peter, Boyanova, Lyudmila, Kunovský, Lumír, Beglinger, Christoph, Doulberis, Michael, Marlicz, Wojciech, Goldis, Adrian, Tonkić, Ante, Capelle, Lisette, Puig, Ignasi, Megraud, Francis, and Morain, Colm O’
Abstract: Background & Aims: After a first Helicobacter pylori eradication attempt, approximately 20% of patients will remain infected. The aim of the current study was to assess the effectiveness and safety of second-line empiric treatment in Europe. Methods: This international, multicenter, prospective, non-interventional registry aimed to evaluate the decisions and outcomes of H pylori management by European gastroenterologists. All infected adult cases with a previous eradication treatment attempt were registered with the Spanish Association of Gastroenterology–Research Electronic Data Capture until February 2021. Patients allergic to penicillin and those who received susceptibility-guided therapy were excluded. Data monitoring was performed to ensure data quality. Results: Overall, 5055 patients received empiric second-line treatment. Triple therapy with amoxicillin and levofloxacin was prescribed most commonly (33%). The overall effectiveness was 82% by modified intention-to-treat analysis and 83% in the per-protocol population. After failure of first-line clarithromycin-containing treatment, optimal eradication (>90%) was obtained with moxifloxacin-containing triple therapy or levofloxacin-containing quadruple therapy (with bismuth). In patients receiving triple therapy containing levofloxacin or moxifloxacin, and levofloxacin–bismuth quadruple treatment, cure rates were optimized with 14-day regimens using high doses of proton pump inhibitors. However, 3-in-1 single capsule or levofloxacin–bismuth quadruple therapy produced reliable eradication rates regardless of proton pump inhibitor dose, duration of therapy, or previous first-line treatment. The overall incidence of adverse events was 28%, and most (85%) were mild. Three patients developed serious adverse events (0.3%) requiring hospitalization. Conclusions: Empiric second-line regimens including 14-day quinolone triple therapies, 14-day levofloxacin–bismuth quadruple therapy, 14-day tetracycline–bismuth
Published: 2022

45. Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg).

Author: Burgos-Santamaría, Diego, Nyssen, Olga P., Gasbarrini, Antonio, Vaira, Dino, Pérez-Aisa, Ángeles, Rodrigo, Luís, Pellicano, Rinaldo, Keco-Huerga, Alma, Pabón-Carrasco, Manuel, Castro-Fernandez, Manuel, Boltin, Doron, Barrio, Jesus, Phull, Perminder, Kupcinskas, Juozas, Jonaitis, Laimas, Ortiz-Polo, Inmaculada, Tepes, Bojan, Lucendo, Alfredo J., María Huguet, José, and Areia, Miguel
Subjects: HELICOBACTER pylori infections, HELICOBACTER pylori, PATIENTS' attitudes, MEDICAL sciences, MEDICAL education, TREATMENT effectiveness
Published: 2023
Full Text: View/download PDF

46. Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacterpylori Infection (Hp-EuReg)

Author: Fernández-Salazar, Luis, primary, Campillo, Ana, additional, Rodrigo, Luis, additional, Pérez-Aisa, Ángeles, additional, González-Santiago, Jesús, additional, Segarra Ortega, Xavier, additional, Denkovski, Maja, additional, Brglez Jurecic, Natasa, additional, Bujanda, Luis, additional, Gómez Rodríguez, Blas, additional, Ortuño, Juan, additional, Georgopoulos, Sotirios, additional, Jonaitis, Laimas, additional, Puig, Ignasi, additional, Nyssen, Olga P., additional, Megraud, Francis, additional, O’Morain, Colm, additional, and Gisbert, Javier P., additional
Published: 2022
Full Text: View/download PDF

47. Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis

Author: Nyssen, Olga P., primary, Espada, Marta, additional, and Gisbert, Javier P., additional
Published: 2022
Full Text: View/download PDF

48. V Spanish Consensus Conference on Helicobacter pylori infection treatment

Author: Gisbert, Javier P., primary, Alcedo, Javier, additional, Amador, Javier, additional, Bujanda, Luis, additional, Calvet, Xavier, additional, Castro-Fernández, Manuel, additional, Fernández-Salazar, Luis, additional, Gené, Emili, additional, Lanas, Ángel, additional, Lucendo, Alfredo, additional, Molina-Infante, Javier, additional, Nyssen, Olga P., additional, Pérez-Aisa, A., additional, and Puig, Ignasi, additional
Published: 2022
Full Text: View/download PDF

49. Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)

Author: Nyssen, Olga P., Vaira, Dino, Saracino, Ilaria María, Fiorini, Giulia, Caldas, María, Bujanda, Luis, Pabón Carrasco, Manuel, Gisbert, Javier P., Universidad de Sevilla. Departamento de Enfermería, and Universidad de Sevilla. CTS1054: Intervenciones y cuidados de la salud. Cruz Roja.
Subjects: Treatment, Helicobacter pylori, Rifabutin, Hp-EuReg, Rescue, Culture, Eradication failure, Bismuth, H. pylori
Abstract: Background: First-line Helicobacter pylori (H. pylori) treatments have been relatively well evaluated; however, it remains necessary to identify the most effective rescue treatments. Our aim was to assess the effectiveness and safety of H. pylori regimens containing rifabutin. METHODS: International multicentre prospective non-interventional European Registry on H. pylori Management (Hp-EuReg). Patients treated with rifabutin were registered in AEG-REDCap e-CRF from 2013 to 2021. Modified intention-to-treat and per-protocol analyses were performed. Data were subject to quality control. Results: Overall, 500 patients included in the Hp-EuReg were treated with rifabutin (mean age 52 years, 72% female, 63% with dyspepsia, 4% with peptic ulcer). Culture was performed in 63% of cases: dual resistance (to both clarithromycin and metronidazole) was reported in 46% of the cases, and triple resistance (to clarithromycin, metronidazole, and levofloxacin) in 39%. In 87% of cases rifabutin was utilised as part of a triple therapy together with amoxicillin and a proton-pump inhibitor, and in an additional 6% of the patients, bismuth was added to this triple regimen. Rifabutin was mainly used in second-line (32%), third-line (25%), and fourth-line (27%) regimens, achieving overall 78%, 80% and 66% effectiveness by modified intention-to-treat, respectively. Compliance with treatment was 89%. At least one adverse event was registered in 26% of the patients (most frequently nausea), and one serious adverse event (0.2%) was reported in one patient with leukope nia and thrombocytopenia with fever requiring hospitalisation. Conclusion: Rifabutin-containing therapy represents an effective and safe strategy after one or even several failures of H. pylori eradication treatment.
Published: 2022

50. Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter pylori Infection (Hp-EuReg)

Author: Fernandez-Salazar, Luis, Campillo, Ana, Rodrigo, Luis, Perez-Aisa, Angeles, Gonzalez-Santiago, Jesus M., Segarra Ortega, Xavier, Denkovski, Maja, Brglez Jurecic, Natasa, Bujanda, Luis, Gomez Rodriguez, Blas Jose, Ortuno, Juan, Georgopoulos, Sotirios, Jonaitis, Laimas, Puig, Ignasi, Nyssen, Olga P., Megraud, Francis, O'Morain, Colm, and Gisbert, Javier P.
Published: 2022

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

214 results on '"Nyssen, Olga P."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources